


SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23		SERIAL NO. 10/631,143	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman			
(37 CFR 1.98(b))				FILING DATE July 31, 2003		GROUP 1615	



U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
9/8	A.A	4 0 7 9 0 3 8	03/14/78	Choi et al.	260	47	03/05/76		
	A.B	4 0 9 3 7 0 9	06/06/78	Choi et al	424	19	01/28/75		
	A.C	4 1 3 1 6 4 8	12/28/78	Choi et al	424	22	03/02/78		
	A.D	4 1 3 8 3 4 4	02/06/79	Choi et al	252	1	08/24/77		
	A.E	4 1 8 0 6 4 6	12/25/79	Choi et al	528	153	03/03/78		
	A.F	4 3 0 4 7 6 7	12/08/81	Heller et al	424	78	05/15/80		
	A.G	4 9 4 6 9 3 1	08/07/90	Heller et al	528	320	06/14/89		
	A.H	5 2 9 4 6 0 4	03/15/94	Nussenblatt et al.	514	11	12/20/89		
	A.I	5 4 1 1 9 5 2	05/1995	Kaswan	—	—			
	A.J	5 4 5 7 1 8 2	10/10/95	Wiederrecht et al.	530	402	02/15/94		
	A.K	5 7 7 0 6 0 7	06/23/98	Honbo et al.	514	302	07/18/94		
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS									
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)		
9/8	A.L	JP 07010752 Abstract	01/13/95	JP	A61K	31/365	N/A		
	A.M	JP 09315954 Abstract	12/09/97	JP	A61K	9/08	N/A		
	A.N	WO 99/22722	05/14/99	WO	A61K	31/00	N/A		
	A.O	AU 17388/88	Unknown	AU	Unknown	Unknown	N/A		
	A.P	AU 20350/92	Unknown	AU	Unknown	Unknown	N/A		
	A.Q	CN 1333018	01/30/02	CN	A61K	9/06	Abstract only		
	OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)								
9/8	A.R	Algvere et al., Long-term outcome of RPE allografts in non-immunosuppressed patients with AMD, European J of Ophthalmology (1999) 9(3):217-230							
	A.S	Anderson et al., A Role for Local Inflammation in the Formation of Drusen in the Aging Eye, American Journal of Ophthalmology, Vol. 134, No. 3, September 2002, pp. 411-431							
	A.T	Aramant et al., Retinal transplanatation, Science & Medicines (2000), 7:20-29							
EXAMINER <i>Hurcia J. Preick</i>				DATE CONSIDERED 02/24/06					

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23		SERIAL NO. 10/631,143							
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman									
				FILING DATE July 31, 2003		GROUP 1615							
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		PATENT NUMBER							ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A	5	7	7	3	0	1	9	06/30/98	Ashton et al	424	423	09/27/95
	B.B	5	9	5	2	3	7	1	09/14/99	Baker et al.	514	443	10/08/97
	B.C	5	9	6	8	5	4	3	10/19/99	Heller et al.	424	425	12/05/97
	B.D	6	0	0	4	5	6	5	12/21/99	Chiba et al.	424	278.1	09/23/97
	B.E	6	1	7	9	8	1	7	01/30/01	Zhong	604	265	01/28/99
	B.F	6	2	3	9	1	1	3	05/29/01	Dawson et al.	514	29	06/02/99
	B.G	6	2	3	8	7	9	9	05/29/01	Opolski	428	423	02/07/97
	B.H	6	2	5	8	8	5	6	07/10/01	Chamberlain et al	514	912	07/10/01
	B.I	6	3	0	6	4	2	2	10/23/01	Batich et al	424	423	08/03/98
	B.J	6	3	5	0	4	4	2	02/26/02	Garst	424	78.04	05/30/01
	B.K	6	4	1	3	5	3	6	07/02/02	Gibson et al	424	423	08/27/99
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS													
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)						
	B.L	CN 1340358	03/20/03	CN	A61K	38/13	Abstract only						
	B.M	CN 1456350	11/19/2003	CN	A61K	9/00	Abstract only						
	B.N	DE 19810655	09/16/99	DE	A61K	38/13	Abstract only						
	B.O	EP 1142566	10/10/01	EP	A61K	9/08	Abstract only						
	B.P	JP 10218787	08/18/98	JP	A61K	38/22	Yes						
	B.Q	JP 1997030966	02/04/97	JP	A61K	31/365	Yes						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)													
	B.R	Aron-Rosa, <u>Pulsed Nd:YAG lasers in ophthalmology</u> , Nd:YAG Laser Applications pp. 34-48 (1986)											
	B.S	Carmo et al., <u>Effect of cyclosporin A on the blood-retinal barrier permeability in streptozotocin-induced diabetes</u> , Mediators of Inflammation (2000), 9(5):243-248											
	B.T	Chiou, <u>Topical Treatment of Ocular Hypertension, Glaucoma, Ischemic Retinopathy and Age-Related Macular Degeneration with Ophthalmic Formulation of Dopamine Antagonists</u> , U.S. Patent Publication No. US 2003/0069232, published 04/10/03											
EXAMINER 					DATE CONSIDERED 02/24/06								
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.													

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman		
(37 CFR 1.98(b))				FILING DATE July 31, 2003	GROUP 1615	

U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		PATENT NUMBER							ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JS	C.A	6	4	3	6	9	0	6	08/20/02	Or et al	514	29	04/02/01
	C.B	6	4	4	0	9	4	2	08/27/02	Or et al	514	30	12/22/00
	C.C	6	4	6	2	0	7	1	10/2002	Castillejos	—	—	
	C.D	6	4	6	2	0	2	6	10/08/02	Or et al	514	30	02/16/01
	C.E	6	4	8	2	7	9	9	11/2002	Tuse et al	—	—	
	C.F	6	5	3	4	6	9	3	03/18/03	Fischell et al.	A61F	13/00	01/31/01
	C.G	6	5	9	6	2	9	6	07/22/03	Nelson et al	424	425	08/04/00
	C.H	6	6	1	3	3	5	5	09/02/03	Ng et al	424	462	05/11/01
	C.I	6	6	1	7	3	4	5	09/09/03	Gregory et al	514	395	09/12/00
	C.J	6	6	6	7	3	7	1	12/23/03	Ng et al	525	462	11/14/02
JS	C.K	6	6	7	0	3	9	8	12/2003	Edwards et a	—	—	

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
JS	C.L	JP 2001064198	03/13/01	JP	A61K	38/22	Yes
	C.M	WO 02/24234	03/28/02	PCT WO	A61K	48/00	N/A
	C.N	WO 03/051385	06/26/03	PCT WO	A61K	38/13	Abstract only
	C.O	WO 03/017990	03/06/03	PCT WO	A61K	31/00	N/A
	C.P	WO 2004/096261	11/11/24	PCT WO	A61K	38/13	Abstract only
JS	C.Q	WO 2004/043480	05/27/04	PCT WO	A61K	38/00	N/A

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)	
JS	C.R Ciccirell et al., <u>Pharmacokinetics of subconjunctivally administered cyclosporine A. Local delivery prior to chemotherapy for retinoblastoma</u> , IOVS (3/15/2001), 42(4):S332
JS	C.S Costantini, LC, et al., <u>Immunophilin Ligands and GDNF Enhance Neurite Branching or Elongation from Developing Dopamine Neurons in Culture</u> , Experimental Neurology 164,60-70 (2000)
JS	C.T Das et al., <u>The transplantation of human fetal neuroretinal cells in advanced retinitis pigmentosa patients: Results of a long-term safety study</u> , Experimental Neurology (1999), 157:58-68

EXAMINER	DATE CONSIDERED 02/24/06
----------	--------------------------




EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.


SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23		SERIAL NO. 10/631,143							
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman									
				FILING DATE July 31, 2003		GROUP 1615							
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		PATENT NUMBER			ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	D.A	6	6	7	3	8	0	7	01/2004	Sakai et al			
	D.B	6	7	1	3	0	8	1	03/2004	Robinson et al			
	D.C												
	D.D												
	D.E												
	D.F												
	D.G												
	D.H												
	D.I												
	D.J												
	D.K												
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS													
		DOCUMENT NUMBER			PUBLICATION DATE		COUNTRY OR PATENT OFFICE		CLASS	SUBCLASS	TRANSLATION (YES/NO)		
	D.L	WO 2005/030205			04/07/05		PCT WO		A61K	31/436	N/A		
	D.M	WO 2005/011813			02/10/05		PCT WO		A61P	27/02	N/A		
	D.N	WO 89/01772			03/02/89		PCT WO		A61K	9/00	N/A		
	D.O	WO 99/42104			08/26/99		PCT WO		A61K	31/435	N/A		
	D.P												
	D.Q												
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)													
	D.R	Del Cerro et al., <u>Histologic correlation of human neural retinal transplantation</u> , Invest. Ophthalmology & Visual Science (2000) 41(10): 3142-3148											
	D.S	Dewey, 2003 PCO Update: Part 1 - <u>How the square-edged IOL prevents posterior capsular opacification</u> , Cataract & Refractive Surgery Today, September 2003, pp. 20-22											
	D.T	Donnenfeld et al., <u>Cyclosporine provides effective treatment for dry eye</u> , Therapeutic Updates in Ophthalmology, Special Issue, July 1999, pp. 1-3											
EXAMINER						DATE CONSIDERED							
						02/24/06							
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.													

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23		SERIAL NO. 10/631,143	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman			
(37 CFR 1.98(b))				FILING DATE July 31, 2003		GROUP 1615	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	E.A						
	E.B						
	E.C						
	E.D						
	E.E						
	E.F						
	E.G						
	E.H						
	E.I						
	E.J						
	E.K						





FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	E.L						
	E.M						
	E.N						
	E.O						
	E.P						
	E.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
	E.R	Eneydi et al., <u>Pharmacokinetics and toxicity of an intravitreal device providing sustained release of cyclosporine (CsA) and dexamethasone (DEX)</u> , Investigative Ophthalmology and Visual Science, Vol. 35, No. 4, 1994, p. 1906, and Annual Meeting of the association for Research in Vision and Ophthalmology, Sarasota, FL, USA, May 1-6, 1994 abstract
	E.S	Eneydi et al., <u>An intravitreal device providing sustained release of cyclosporine and dexamethasone</u> , Current Eye Research, May 1996, Vol. 15, No. 5, pp. 549-557
	E.T	Garweg et al., <u>Therapy of Goldmann-Favre's Vitreo-Retinal Degeneration with Cyclosporin A and Bromocriptine</u> , Klinische Monatsblätter für Augenheilkunde, Vol. 199, No. 3, September 1991, pp. 199-205

EXAMINER 	DATE CONSIDERED 02/24/06
---	-----------------------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman		
				FILING DATE July 31, 2003		GROUP 1615
(37 CFR 1.98(b))						
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	FILING DATE IF APPROPRIATE
	F.A					
	F.B					
	F.C					
	F.D					
	F.E					
	F.F					
	F.G					
	F.H					
	F.I					
	F.J					
	F.K					
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS						
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	TRANSLATION (YES/NO)
	F.L					
	F.M					
	F.N					
	F.O					
	F.P					
	F.Q					
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)						
	F.R	Gilbard, <u>EW Interview: Electrolyte balance is key to dry-eye product's success</u> , EyeWorld, February 1999, pp. 20ff				
	F.S	Grisolano et al., <u>Retinal Toxicity Study of Intravitreal Cyclosporin</u> , Ophthalmic Surgery, March 1986, 17:155-156				
	F.T	Hageman et al., <u>Diagnostics and Therapeutics for Macular Degeneration-Related Disorders</u> , U.S. Patent Application Publication No. US 2-2/0015957, published 02/07/02				
EXAMINER 				DATE CONSIDERED 02/24/06		
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.						

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman			
				FILING DATE July 31, 2003		GROUP 1615	
(37 CFR 1.98(b))							
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	G.A						
	G.B						
	G.C						
	G.D						
	G.E						
	G.F						
	G.G						
	G.H						
	G.I						
	G.J						
	G.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	G.L						
	G.M						
	G.N						
	G.O						
	G.P						
	G.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	G.R	Jiang et al, <u>Corneal electroretinographic function rescued by normal retinal pigment epithelial grafts in retinal degenerative Royal College of Surgeons rats</u> , Invest. Ophthalmology & Visual Science (1994). 35(13):4300-4308					
	G.S	Karacortu et al, <u>Lack of toxicity of intravitreally administered interferon Alpha-2a</u> , Ophthalmic Surgery (1999) 23:833-835					
	G.T	Keep et al, <u>Introduction: Immunosuppressants as Neuroprotective Agents, Immunosuppressant Analogs in Neuroprotection, Part I: Immunosuppressants, Neurologic Disorders, and Neuroprotection</u> , Ed. Borlongan & Sanberg, Humana Press Inc., Totowa NJ, pp.3-32 (11/2002)					
EXAMINER					DATE CONSIDERED		
					02/24/06		
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman		
(37 CFR 1.98(b))				FILING DATE July 31, 2003	GROUP 1615	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	H.A						
	H.B						
	H.C						
	H.D						
	H.E						
	H.F						
	H.G						
	H.H						
	H.I						
	H.J						
	H.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	H.L						
	H.M						
	H.N						
	H.O						
	H.P						
	H.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
9/5	H.R	Kiryu et al., <u>In Vivo Evaluation of the Inhibitory Effects of Tacrolimus (FK506) on Leukocyte Accumulation During Retinal Ischemia Reperfusion Injury</u> , Poster Presentation 1247-B128 (03/1998)
9/5	H.S	Lai et al, <u>Local immunosuppression prolongs survival of RPE xenografts labeled by retroviral gene transfer</u> , IOVS (9/2000) 41(10):3134-3141
9/5	H.T	Lallemant et al., <u>Cyclosporine A delivery to the eye: A pharmaceutical challenge</u> , European Journal of Pharmaceutics and Biopharmaceutics, 56 (2003), pp. 307-318

EXAMINER 	DATE CONSIDERED 02/24/06
--------------	-----------------------------




EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.


SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Gholam Peyman			
(Use several sheets if necessary)				FILING DATE July 31, 2003	GROUP 1615		
(37 CFR 1.98(b))							
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	I.A						
	I.B						
	I.C						
	I.D						
	I.E						
	I.F						
	I.G						
	I.H						
	I.I						
	I.J						
	I.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	I.L						
	I.M						
	I.N						
	I.O						
	I.P						
	I.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
EXAMINER	I.R	Lipner, <u>Dry Eye 101: Developing etiologies and treatments for this widespread syndrome</u> , EyeWorld, February 1999, pp. 19ff					
I.S	Lipper et al., <u>Recent therapeutic advances in dermatology</u> , JAMA, Vol, 283, No. 2, January 12, 2000, pp. 175-177						
I.T	Lopez et al., <u>Transplanted retinal pigment epithelium modifies the retinal degeneration in the RCS</u> , Invest. Ophthalmology & Visual Science (1989), 30:586-588						
EXAMINER <i>Gholam Peyman</i>				DATE CONSIDERED <i>02/24/06</i>			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23		SERIAL NO. 10/631,143	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Gholam Peyman			
(37 CFR 1.98(b)) (Use several sheets if necessary)				FILING DATE July 31, 2003		GROUP 1615	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	J.A						
	J.B						
	J.C						
	J.D						
	J.E						
	J.F						
	J.G						
	J.H						
	J.I						
	J.J						
	J.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	J.L						
	J.M						
	J.N						
	J.O						
	J.P						
	J.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
	J.R	Lund, et al., <u>Subretinal transplantation of genetically modified human cell lines attenuates loss of visual function in dystrophic rats</u> , PNCS (2001), 98(17): 9942-9947
	J.S	Martin DF et al., <u>Synergistic Effect of Rapamycin and Cyclosporin A in the Treatment of Experimental Autoimmune Uveoretinitis</u> , The Journal of Immunology, 1995, 154:922-927
	J.T	Nicoletti et al., <u>The effects of deoxyspergualin on the development of diabetes in diabetes-prone BB rats</u> , Scandinavian Journal of Immunology (1992) 36(3):415-420

EXAMINER 	DATE CONSIDERED 02/24/06
---	-----------------------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23		SERIAL NO. 10/631,143	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman			
(37 CFR 1.98(b))				FILING DATE July 31, 2003		GROUP 1615	


U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
K.A							
K.B							
K.C							
K.D							
K.E							
K.F							
K.G							
K.H							
K.I							
K.J							
K.K							





FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)		
K.L							
K.M							
K.N							
K.O							
K.P							
K.Q							

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
K.R	Passos et al., <u>Ocular Toxicity of Intravitreal Tacrolimus</u> , Ophthalmic Surgery and Lasers, March/April 2002, Vol. 22, No. 2, pp. 140-144	
K.S	PCT, <u>International Search Report</u> , PCT/US03/28315, mailed 06/15/04, 6 pages	
K.T	Peyman et al., <u>Intravitreal Surgery</u> , Principles and Practice, 2nd Edition, 1994, Ppleton & Lange, Connecticut, pp. 443-452	

EXAMINER 	DATE CONSIDERED <div style="text-align: right; font-size: 1.2em;">02/24/06</div>
--------------	---

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.




SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Gholam Peyman			
(Use several sheets if necessary)				FILING DATE July 31, 2003	GROUP 1615		
(37 CFR 1.98(b))							
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	LA						
	LB						
	LC						
	LD						
	LE						
	LF						
	LG						
	LH						
	LI						
	LJ						
	LK						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	LL						
	LM						
	LN						
	LO						
	LP						
	LQ						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
JS	LR	Peyman et al., <u>Keratitis (Noninfectious)</u> , Principles and Practice of Ophthalmology, W.B. Saunders Company, 1980, pp. 446-449					
JS	LS	Peyman et al., <u>Intravitreal drug therapy</u> , Japanese Journal of Ophthalmology (1989), 33(4): 392-404					
JS	LT	Peyman, <u>Treatment of Ocular Disease</u> , U.S. Application Publication No. 2004/0092435, published 05/13/04, Serial No. 10/289,772, filed 11/07/02					
EXAMINER				DATE CONSIDERED			
				02/24/06			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							


SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman			
				FILING DATE July 31, 2003	GROUP 1615		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	M.A						
	M.B						
	M.C						
	M.D						
	M.E						
	M.F						
	M.G						
	M.H						
	M.I						
	M.J						
	M.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	M.L						
	M.M						
	M.N						
	M.O						
	M.P						
	M.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	M.R	Peyman, <u>Treatment of Ocular Disease</u> , U.S. Application Publication No. 2005/0025810, published 02/03/05, Serial No. 10/631,143, filed 07/31/03					
	M.S	Peyman, <u>Ocular Solutions</u> , U.S. Application Publication No. 2005/0063997, published 03/24/05, Serial No. 10/752,124, filed 01/06/04					
	M.T	Peyman, <u>Ocular Solutions</u> , U.S. Application Publication No. 2005/0063996, published 03/24/05, Serial No. 10/667,161, filed 09/19/03,					
EXAMINER 				DATE CONSIDERED 02/24/06			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23		SERIAL NO. 10/631,143	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman			
(37 CFR 1.98(b))				FILING DATE July 31, 2003		GROUP 1615	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	N.A						
	N.B						
	N.C						
	N.D						
	N.E						
	N.F						
	N.G						
	N.H						
	N.I						
	N.J						
	N.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	N.L						
	N.M						
	N.N						
	N.O						
	N.P						
	N.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
  	N.R	Peyman, <u>Pupillary Membranes: Nd:YAG Capsulotomy</u> , Intravitreal Surgery, Norwalk CT, Appleton & Lange, 1994, pp. 253-257
	N.S	Peyman et al., <u>Implantation of a sustained-release ganciclovir implant</u> , Vitreoretinal Surgical Techniques, Martin Dunitz Ltd., 2001, Chapter 45, pp. 521-531
	N.T	Schonfield and Kirst, <u>Macrolide Antibiotics</u> , Birkhausen, Basil, Switzerland, 2002, pp. 1-36

EXAMINER 	DATE CONSIDERED 02/24/06
---	-----------------------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PMAN/23SERIAL NO.
10/631,143INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Gholam Peyman

(Use several sheets if necessary)

FILING DATE
July 31, 2003GROUP
1615

(37 CFR 1.98(b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	O.A						
	O.B						
	O.C						
	O.D						
	O.E						
	O.F						
	O.G						
	O.H						
	O.I						
	O.J						
	O.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	O.L						
	O.M						
	O.N						
	O.O						
	O.P						
	O.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	O.R	Shen et al., <u>Combined effect of cyclosporine and sirolimus on improving the longevity of recombinant adenovirus-mediated transgene expression in the retina</u> , Archives of Ophthalmology (7/2001), 119(7): 1033-1043
	O.S	Stosic-Grujicic et al, <u>Leflunomide protects mice from multiple low dose streptozotocin (MLD-SA)-induced insulinitis and diabetes</u> , Clinical & Experimental Immunology (1999) 117(1):44-50
	O.T	Ueno, <u>Composition for Topical Administration</u> , U.S. Patent Application Publication No. US2003/0044452 published 03/06/03, Serial No. 10/187,013, filed 07/02/02

EXAMINER

DATE CONSIDERED

02/24/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam Peyman			
				FILING DATE July 31, 2003	GROUP 1615		
(37 CFR 1.98(b))							
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	P.A						
	P.B						
	P.C						
	P.D						
	P.E						
	P.F						
	P.G						
	P.H						
	P.I						
	P.J						
	P.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	P.L						
	P.M						
	P.N						
	P.O						
	P.P						
	P.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	P.R	Wakelee-Lynch, <u>Interferon may offer first drug therapy for diabetic retinopathy</u> , Diabetes Care (1992), 15(2):300-301					
	P.S	Wise, <u>Handbook of Pharmaceutical Controlled Release Technology</u> , Marcel Dekker, New York, 2000					
	P.T						
EXAMINER 				DATE CONSIDERED 02/24/06			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							